Jennifer Van Brunt, Editor


September 2, 2010


Recap Roundup: 1Q 2010
Recap Roundup:
1Q 2010

What’s the meaning of Euthymics Bioscience’s name?



In The Spotlight:
A rotating collection of articles from Signals’ archives on selected topics of interest.

Who's On First
A handy guide that tracks recent name changes in the biotech sector.



NEWS LINKS
PRNewswire
BioSpace News
Yahoo! Finance
Signals Magazine
is published by
Recap

COVER STORY
Steady As She Goes

Biotech and specialty pharma firms raised nearly $14 billion in the first half of 2010 – and if the pace continues for the rest of the year, it could be a record-breaker.



Recap IQ Series by Deloitte

Recap IQ Series by Deloitte Intelligent toolkits for biopharmaceutical business intelligence. Tools for alliance and clinical development strategies.


Allicense 2010

Redefining the Threshold of Innovation May 25 & 26 2010 San Francisco Conference Concluded Thank You Speakers & Attendees



Biotech Drug Approvals: A Year Of Firsts
The FDA approved more new biotech and biotech-related therapies in 2009 than it had since at least 2000 – and many of them address previously untreatable diseases.

Flu Fighters
We have never been more prepared to take on the flu than we are now – but will the new vaccines and drugs be enough to forestall a virulent pandemic?

Chipping Away At Biotech Blockbusters
The global recession has finally affected the sales of dozens of blockbuster drugs developed and marketed by biotech and big pharma companies. More often than not, though, unfavorable currency exchange rates – rather than lower sales volumes -- accounted for the losses.



© 2010 Signals Magazine